ClinicalTrials.gg
CompletedNCT05074888Updated Sep 23, 2024Results posted

Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.

A Phase 3 interventional study of Prospekta and Placebo in Post-acute COVID-19 Syndrome, sponsored by Materia Medica Holding. Completed at 32 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
676
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial.

The objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the coronavirus infectious disease (COVID-19).

Read the detailed description

Design: the multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial.

The study will enroll adult patients of either gender aged 18 to 65 years after new coronavirus infection of 2019 (COVID-19) with symptoms of asthenia that appeared during or after an acute coronavirus infection (COVID-19) and persisting 4 to 12 weeks from the onset of coronavirus infection.

After the patient signs the patient information sheet and the informed consent form for participation in the study, complaints, medical history, physical examination, registration of vital signs are collected, the patient fills in the Fatigue Severity Scale (FSS) and Hospital Anxiety and Depression Scale (HADS). A six-minute walk test (6MWT) is carried out. The physician evaluates the severity of asthenia with FSS scale and records concomitant medications, co-morbidities and concurrent conditions.

If a patient meets all inclusion criteria and does not have any of the exclusion criteria at Visit 1 (Day 1), he/she is randomized to one of two groups: Group 1 - patients receive Prospekta at a dose of 1 tablet twice daily for 4 weeks; Group 2 - patients receive placebo on the study drug regimen.

The trial will use electronic patient diaries (EPD). The patient should record any possible deterioration (if applicable) in the EPD. At Visit 1 (Day 1), the physician will provide guidance on how to work with EPD, so that the patient can use it independently in the future.

At Visit 2 (Week 4 ± 3 days), the physician will collect patient's complaints, record physical examination data and vital signs as well as any changes in concurrent diseases and conditions. The patient fills out the FSS and HADS scales. A 6MWT is carried out. The physician monitors the prescribed treatment and use of concomitant medications, evaluates the safety of the study treatment and patient's compliance, filling out the diary.

The patient stops taking the study drug. At the end of the study treatment period, the patient is monitored for 4 weeks (follow-up period).

At Visit 3 (final visit, Week 8 ± 3 days), the physician collects patient's complaints, records physical examination data and vital signs, changes in concomitant diseases and conditions. The patient fills in the FSS and HADS scales. A 6MWT is carried out. The physician evaluates the safety of the study treatment, checks the completion of the diary.

During the study the patients are allowed to take medications for their chronic conditions, except for medicines listed as "Prohibited concomitant treatment".

02

Conditions studied

  • Post-acute COVID-19 Syndrome
03

In context

Post-Acute COVID-19 Syndrome

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's enrollment of 676 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults of either gender aged 18 to 65 years inclusive.
  2. Patients within 4-12 weeks of the confirmed COVID-19 onset .
  3. Symptoms of asthenia that appeared during or after an acute new coronavirus infection (COVID-19), persisting from 4 to 12 weeks from the onset of coronavirus infection.
  4. Presence of asthenia (≥36 on the FSS scale).
  5. Patients who agreed to use a reliable method of during the study (for men and women with ).
  6. Presence of a signed information sheet and form for participation in a clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. History / suspicion of cancer of any localization (with the exception of benign neoplasms).
  2. More than 75% of lung tissue damage during the period of COVID-19 disease (CT 4).
  3. Cerebrovascular diseases with the development of moderate to severe cognitive impairments.
  4. Uncontrolled arterial hypertension characterized by the following blood tension values: systolic blood pressure > 180 mm Hg and/or diastolic blood pressure > 110 mm Hg.
  5. Myocardial infarction, stroke in the previous 6 months.
  6. Nervous system disorders with persistent neurological impairment.
  7. diseases.
  8. Decompensated diseases of the cardiovascular system, liver, kidney, gastrointestinal tract, and metabolic, respiratory, endocrine or hematological diseases, peripheral vascular disorders.
  9. Any severe comorbidity which, in the opinion of the investigator, may affect patient participation in the clinical trial.
  10. to any of the components of the study drug.
  11. Hereditary lactose intolerance, lactose malabsorption, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
  12. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use methods during the trial (for men and women with ).
  13. Patients, who, from the investigator's point of view, will not comply with study observation requirements or study drug administration procedures..
  14. Prior history of mental illness, alcoholism or drug abuse, that the investigator's opinion, will interfere with successful study procedures.
  15. Use of any medications listed in "Prohibited concomitant treatment" within 1 week before enrollment.
  16. Participation in other clinical studies within 3 months prior to enrollment in the study.
  17. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. "Immediate relative" means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).
  18. Participants who work for OOO "NPF "MATERIA MEDICA HOLDING" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
676 participants (actual)

Study arms

  • Experimental
    Prospekta

    Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15 minutes before eating or drinking), keep the tablets in the mouth, without swallowing, until completely dissolved.

    Drug: Prospekta

  • Placebo comparator
    Placebo

    Tablet for oral use. Placebo using Prospekta scheme.

    Drug: Placebo

Interventions

  • DrugProspekta

    Oral administration.

  • DrugPlacebo

    Oral administration.

06

What researchers measure

Primary outcomes

  1. Change in the Mean FSS Score.

    Fatigue Severity Scale (FSS). Change in the mean FSS score after 4 weeks of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.

    Time frame: after 4 weeks of treatment

Secondary outcomes

  1. Change in Distance of the 6-minute Walk Test.

    Change in distance when performing the 6-minute walk test after 4 weeks of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.

    Time frame: after 4 weeks of treatment

  2. Change in the Severity of Anxiety on the HADS Subscale.

    Hospital Anxiety and Depression Scale (HADS). Change in the severity of anxiety and depression on the HADS subscales after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

    Time frame: after 4 weeks of treatment

  3. Change in the Severity of Depression on the HADS Subscale.

    Hospital Anxiety and Depression Scale (HADS). Change in the severity of depression on the HADS subscale after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

    Time frame: after 4 weeks of treatment

  4. Change in the Mean FSS Score Within Follow-up Period.

    Change in mean FSS score over 4 weeks of follow-up period at the end of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.

    Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8

  5. Change in Distance of the 6-minute Walk Test Within Follow-up Period.

    Change in distance when performing the 6-minute walk test over a 4-week follow-up period at the end of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.

    Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8

  6. Change in the Severity of Anxiety on the HADS Subscales Within Follow-up Period.

    Change in the severity of anxiety on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

    Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8

  7. Change in the Severity of Depression on the HADS Subscales Within Follow-up Period.

    Change in the severity of depression on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

    Time frame: after 4 weeks of treatment and after 4 weeks of follow-up at week 8

  8. Changes in Vital Signs (Pulse Rate (Heart Rate)).

    Based on medical records. Vital signs will be measured in a medical setting.

    Time frame: after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment.

  9. Changes in Vital Signs (Respiration Rate (Breathing Rate)).

    Based on medical records. Vital signs will be measured in a medical setting.

    Time frame: after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment (Visit 1: baseline, Visit 2: after 4 weeks of treatment, and Visit 3: after 4 weeks of follow-up at week 8)

  10. Changes in Vital Signs (Blood Pressure).

    Based on medical records. Vital signs will be measured in a medical setting.

    Time frame: after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment (Visit 1: baseline, Visit 2: after 4 weeks of treatment, and Visit 3: after 4 weeks of follow-up at week 8).

  11. Presence of Adverse Events (AEs).

    The number of participants with adverse events (AEs). Based on medical records.

    Time frame: 8 weeks

  12. The Severity of AEs.

    The intensity (severity) of adverse events. Based on medical records.

    Time frame: 8 weeks

  13. The Outcome of AEs.

    The outcome of adverse events. Based on medical records.

    Time frame: 8 weeks

  14. AEs Causal Relationship to the Study Drug.

    The adverse events causal relationship to the study drug. Based on medical records.

    Time frame: 8 weeks

07

Results

Posted Sep 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneProspektaPlacebo
Started330346
Completed330346
Not completed00

Outcome measures

PrimaryChange in the Mean FSS Score.

Fatigue Severity Scale (FSS). Change in the mean FSS score after 4 weeks of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.

Time frame:
after 4 weeks of treatment
Reported as:
Mean · score on a scale
Change in the Mean FSS Score.
score on a scaleProspektaPlacebo
Baseline46.4 ± 6.945.9 ± 6.6
After 4 weeks29.9 ± 9.231.9 ± 9.9
∆ between baseline and 4 weeks later16.5 ± 9.514.0 ± 9.4
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0016
SecondaryChange in Distance of the 6-minute Walk Test.

Change in distance when performing the 6-minute walk test after 4 weeks of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.

Time frame:
after 4 weeks of treatment
Reported as:
Mean · meters
Change in Distance of the 6-minute Walk Test.
metersProspektaPlacebo
Baseline426.4 ± 119.2416.9 ± 112.8
After 4 weeks457.8 ± 118.2444.7 ± 110.7
∆ between baseline and 4 weeks later31.4 ± 44.527.8 ± 38.1
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.3183
SecondaryChange in the Severity of Anxiety on the HADS Subscale.

Hospital Anxiety and Depression Scale (HADS). Change in the severity of anxiety and depression on the HADS subscales after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

Time frame:
after 4 weeks of treatment
Reported as:
Mean · score on a scale
Change in the Severity of Anxiety on the HADS Subscale.
score on a scaleProspektaPlacebo
Baseline8.5 ± 4.18.8 ± 3.9
After 4 weeks5.5 ± 3.26.0 ± 3.3
∆ between baseline and 4 weeks later3.0 ± 3.22.8 ± 3.1
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5805
SecondaryChange in the Severity of Depression on the HADS Subscale.

Hospital Anxiety and Depression Scale (HADS). Change in the severity of depression on the HADS subscale after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

Time frame:
after 4 weeks of treatment
Reported as:
Mean · score on a scale
Change in the Severity of Depression on the HADS Subscale.
score on a scaleProspektaPlacebo
Baseline8.1 ± 3.78.3 ± 3.8
After 4 weeks4.7 ± 2.95.2 ± 3.0
∆ between baseline and 4 weeks later3.4 ± 3.03.1 ± 3.1
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.2143
SecondaryChange in the Mean FSS Score Within Follow-up Period.

Change in mean FSS score over 4 weeks of follow-up period at the end of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.

Time frame:
after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Reported as:
Mean · score on a scale
Change in the Mean FSS Score Within Follow-up Period.
score on a scaleProspektaPlacebo
After 4 weeks29.9 ± 9.231.9 ± 9.9
After 8 weeks22.9 ± 9.025.0 ± 10.2
∆ between value after 4 weeks and after 8 weeks7.1 ± 6.37.0 ± 6.9
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.8156
SecondaryChange in Distance of the 6-minute Walk Test Within Follow-up Period.

Change in distance when performing the 6-minute walk test over a 4-week follow-up period at the end of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.

Time frame:
after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Reported as:
Mean · meter
Change in Distance of the 6-minute Walk Test Within Follow-up Period.
meterProspektaPlacebo
After 4 weeks457.8 ± 118.2444.7 ± 110.7
After 8 weeks472.9 ± 116.5462.7 ± 110.1
∆ between value after 4 weeks and after 8 weeks15.9 ± 32.118.8 ± 32.0
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1049
SecondaryChange in the Severity of Anxiety on the HADS Subscales Within Follow-up Period.

Change in the severity of anxiety on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

Time frame:
after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Reported as:
Mean · score on a scale
Change in the Severity of Anxiety on the HADS Subscales Within Follow-up Period.
score on a scaleProspektaPlacebo
After 4 weeks5.5 ± 3.26.0 ± 3.3
After 8 weeks4.0 ± 2.84.4 ± 3.0
∆ between value after 4 weeks and after 8 weeks1.5 ± 2.31.6 ± 2.3
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.7260
SecondaryChange in the Severity of Depression on the HADS Subscales Within Follow-up Period.

Change in the severity of depression on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: "anxiety" (odd items - 1, 3, 5, 7, 9, 11, 13) and "depression" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values: 0-7 - "norm" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - "subclinical anxiety / depression"; 11 and above - "clinical anxiety / depression". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.

Time frame:
after 4 weeks of treatment and after 4 weeks of follow-up at week 8
Reported as:
Mean · score on a scale
Change in the Severity of Depression on the HADS Subscales Within Follow-up Period.
score on a scaleProspektaPlacebo
After 4 weeks4.7 ± 2.95.2 ± 3.0
After 8 weeks3.4 ± 2.63.7 ± 2.8
∆ between value after 4 weeks and after 8 weeks1.4 ± 2.11.5 ± 2.1
Statistical analysis
  • Prospekta vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.6808
SecondaryChanges in Vital Signs (Pulse Rate (Heart Rate)).

Based on medical records. Vital signs will be measured in a medical setting.

Time frame:
after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment.
Reported as:
Mean · beats per minute
Changes in Vital Signs (Pulse Rate (Heart Rate)).
beats per minuteProspektaPlacebo
Visit 1: baseline73.0 ± 6.973.4 ± 6.9
Visit 2: after 4 weeks of treatment71.8 ± 5.871.9 ± 5.6
Visit 3: after 4 weeks of follow-up at week 871.6 ± 5.371.4 ± 5.5
Statistical analysis
  • Prospekta vs Placebo · Mixed Models Analysis · p = 0.54 (The p-value associated with "treatment\*visit" interaction of pulse rate (heart rate) from Visit 1 to 3 between Prospekta and Placebo treatment groups. Model includes treatment, visit and treatment\*visit interaction.)
SecondaryChanges in Vital Signs (Respiration Rate (Breathing Rate)).

Based on medical records. Vital signs will be measured in a medical setting.

Time frame:
after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment (Visit 1: baseline, Visit 2: after 4 weeks of treatment, and Visit 3: after 4 weeks of follow-up at week 8)
Reported as:
Mean · breaths per minute
Changes in Vital Signs (Respiration Rate (Breathing Rate)).
breaths per minuteProspektaPlacebo
Visit 116.3 ± 1.316.4 ± 1.3
Visit 216.2 ± 1.216.2 ± 1.2
Visit 316.2 ± 1.216.2 ± 1.2
Statistical analysis
  • Prospekta vs Placebo · Mixed Models Analysis · p = 0.49 (The p-value associated with "treatment\*visit" interaction of respiration rate (breathing rate) from Visit 1 to 3 between Prospekta and Placebo treatment groups. Model includes treatment, visit and treatment\*visit interaction.)
SecondaryChanges in Vital Signs (Blood Pressure).

Based on medical records. Vital signs will be measured in a medical setting.

Time frame:
after 4 weeks of treatment and within 4 weeks of the follow-up period at the end of the treatment (Visit 1: baseline, Visit 2: after 4 weeks of treatment, and Visit 3: after 4 weeks of follow-up at week 8).
Reported as:
Mean · mmHg
Changes in Vital Signs (Blood Pressure).
mmHgProspektaPlacebo
SBP/Visit 1121.3 ± 8.6120.9 ± 8.3
SBP/Visit 2121.1 ± 8.4120.6 ± 8.1
SBP/Visit 3121.1 ± 8.2120.4 ± 7.4
DBP/Visit 175.8 ± 6.575.8 ± 6.5
DBP/Visit 275.8 ± 6.375.9 ± 6.3
DBP/Visit 376.0 ± 6.175.4 ± 5.9
Statistical analysis
  • Prospekta vs Placebo · Mixed Models Analysis · p = 0.87 (The p-value associated with "treatment\*visit" interaction of systolic blood pressure from Visit 1 to 3 between Prospekta and Placebo treatment groups. Model includes treatment, visit and treatment\*visit interaction.)
  • Prospekta vs Placebo · Mixed Models Analysis · p = 0.22 (The p-value associated with "treatment\*visit" interaction of diastolic blood pressure from Visit 1 to 3 between Prospekta and Placebo treatment groups. Model includes treatment, visit and treatment\*visit interaction.)
SecondaryPresence of Adverse Events (AEs).

The number of participants with adverse events (AEs). Based on medical records.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Presence of Adverse Events (AEs).
ParticipantsProspektaPlacebo
Presence of Adverse Events (AEs).2020
Statistical analysis
  • Prospekta vs Placebo · Fisher Exact · p = 1.0
SecondaryThe Severity of AEs.

The intensity (severity) of adverse events. Based on medical records.

Time frame:
8 weeks
Reported as:
Number · number of AEs
The Severity of AEs.
number of AEsProspektaPlacebo
Mild1315
Moderate1113
Statistical analysis
  • Prospekta vs Placebo · Fisher Exact · p = 1.0
SecondaryThe Outcome of AEs.

The outcome of adverse events. Based on medical records.

Time frame:
8 weeks
Reported as:
Number · number of AEs
The Outcome of AEs.
number of AEsProspektaPlacebo
Recovery/resolution2226
No recovery/resolution20
Unknown02
Statistical analysis
  • Prospekta vs Placebo · Fisher Exact · p = 0.17
SecondaryAEs Causal Relationship to the Study Drug.

The adverse events causal relationship to the study drug. Based on medical records.

Time frame:
8 weeks
Reported as:
Number · number of AEs
AEs Causal Relationship to the Study Drug.
number of AEsProspektaPlacebo
No relation2015
Probable34
Possible10
Doubtful09
Statistical analysis
  • Prospekta vs Placebo · Fisher Exact · p = 0.004

Adverse events

Collected over Reporting of AEs begins after the first dose of IP, continues throughout the study treatment period, and for 4 weeks after the last dose of IP during the follow-up period, up to 8 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prospekta0/330 (0%)0/330 (0%)20/330 (6.1%)
Placebo0/346 (0%)0/346 (0%)20/346 (5.8%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventProspektaPlacebo
HeadacheNervous system disorders3/3304/346
DizzinessNervous system disorders1/3303/346
Viral infection of the respiratory tractInfections and infestations2/3301/346
DrowsinessNervous system disorders2/3300/346
Worsening of hypertensionVascular disorders2/3300/346
Laboratory confirmed coronavirus infection COVID-19Infections and infestations0/3302/346
Epigastric discomfortGastrointestinal disorders1/3300/346
Dry mouthGastrointestinal disorders1/3300/346
Acute respiratory tract infectionInfections and infestations1/3300/346
Acute rhinitisInfections and infestations1/3300/346

Baseline characteristics

Age, Continuous
Age, Continuous(years)ProspektaPlaceboTotal
Mean44.3 ± 12.542.8 ± 12.643.5 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)ProspektaPlaceboTotal
Female216236452
Male114110224
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ProspektaPlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)ProspektaPlaceboTotal
Russia330346676
08

Study locations

32 sites
  • Belgorod Regional Clinical Hospital of St. Joasaph
    Belgorod, 308007, Russian Federation
  • Clinical hospital "RZD-Medicine" of Chelyabinsk city
    Chelyabinsk, 454000, Russian Federation
  • LLC "Family Clinic"
    Ekaterinburg, 620109, Russian Federation
  • Central city hospital # 7
    Ekaterinburg, 620137, Russian Federation
  • Ivanovo clinical hospital named after Kuvaevs/Polyclinic #10
    Ivanovo, 153025, Russian Federation
  • City Clinical Hospital # 9 of the Ministry of Health of the Udmurt Republic
    Izhevsk, 426063, Russian Federation
  • Kazan State Medical University, Department of Propedeutics of Internal Diseases named after prof. S.S. Zimnitsky
    Kazan, 420012, Russian Federation
  • Kazan State Medical University
    Kazan, 420012, Russian Federation
  • Kirov State Medical University, Hospital Therapy Department
    Kirov, 610027, Russian Federation
  • Kuban State Medical University, Infectious Diseases and Phthisiopulmonology
    Krasnodar, 350063, Russian Federation
  • Krasnogorsk city hospital #r 1
    Krasnogorsk, 143408, Russian Federation
  • City Clinical Hospital named after V.M. Buyanov of the Moscow City Health Department
    Moscow, 115516, Russian Federation
  • Central Clinical Hospital of the Russian Academy of Sciences
    Moscow, 117593, Russian Federation
  • Llc "Verum Medical"
    Moscow, 119285, Russian Federation
  • Moscow State Medical and Dental University named after A.I. Evdokimov, Department of Faculty Therapy and Occupational Diseases
    Moscow, 127473, Russian Federation
  • Nizhny Novgorod Research Institute of Hygiene and Occupational Pathology
    Nizhny Novgorod, 603005, Russian Federation
  • Llc "Nizhmedklinika"
    Nizhny Novgorod, 603159, Russian Federation
  • City Emergency Hospital of Rostov-on-Don
    Rostov-on-Don, 344068, Russian Federation
  • Ryazan State Medical University named after acad. I.P. Pavlov, Department of Outpatient Therapy and Preventive Medicine
    Ryazan, 390026, Russian Federation
  • Llc "Ava-Peter"
    Saint Petersburg, 191014, Russian Federation
  • LLC "Energy of Health"
    Saint Petersburg, 194156, Russian Federation
  • LLC Medical center" Reavita Med SPb "
    Saint Petersburg, 194354, Russian Federation
  • City polyclinic # 51
    Saint Petersburg, 196211, Russian Federation
  • City Polyclinic # 34
    Saint Petersburg, 197198, Russian Federation
  • Saratov State Medical University named after V. I. Razumovsky, Neurology Department named after K.N. Tretyakov
    Saratov, 410012, Russian Federation
  • LLC "Scientific Medical Center for General Therapy and Pharmacology"
    Stavropol, 355000, Russian Federation
  • Bashkir State Medical University, Internal Medicine Department
    Ufa, 450008, Russian Federation
  • Ulyanovsk Regional Clinical Hospital
    Ulyanovsk, 432063, Russian Federation
  • Vsevolozhsk clinical interdistrict hospital
    Vsevolozhsk, 188643, Russian Federation
  • LLC "Center for Medical Consulting and Research - PRACTICE"
    Yaroslavl, 150003, Russian Federation
  • Clinical Hospital # 2
    Yaroslavl, 150030, Russian Federation
  • Clinical Hospital # 9
    Yaroslavl, 150042, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jun 2022, 7 months.

Results were first posted in Sep 2024, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2021
First posted
Oct 12, 2021
StartActual
Oct 15, 2021
Primary completionActual
Jun 8, 2022
CompletionActual
Jun 8, 2022
Results first posted
Sep 23, 2024
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05074888
Responsible party
Sponsor
First posted
Oct 12, 2021
Start date
Oct 15, 2021
Primary completion
Jun 8, 2022
Completion
Jun 8, 2022
Results posted
Sep 23, 2024
Last update
Sep 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion